EGFR and posterior cortical atrophy: However while pre-clinical data indicate that EGFR plays a significant role in PCa progression [21]; clinical trials involving EGFR inhibitors (Gefitinib, Lapatinib or Erlotinib) have shown limited benefit to PCa patients [22, 23, 49].